ANTHONY R CHASE
CIK 1223756 · last filed 2026-06-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$4.89M
Companies
10
Total Filings
137
Lifetime Open-Market Net
-$653.4K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NBR | Director | 15,408 | $88.84 | $1.37M | $0 | 12 | 2026-06-03 |
| CFR | Director | 1 | $167.96 | $168 | $109 | 8 | 2026-05-27 |
| LYB | Director | 13,603 | $63.13 | $858.7K | $255 | 23 | 2026-05-26 |
| PARR | Director | 10,529 | $75.10 | $790.7K | $0 | 13 | 2024-10-08 |
| Heritage-Crystal Clean, Inc. (HCCI) Delisted | Director | 1,641 | $45.51 | $74.7K | $0 | 1 | 2021-05-05 |
| APC | Director | 0 | $18.52 | $0 | $288.5K | 13 | 2019-08-09 |
| PARAGON OFFSHORE PLC (PGN) Delisted | Director | 19,616 | — | — | $0 | 5 | 2015-05-05 |
| SRPT | Director | 67,194 | $18.32 | $1.23M | -$389.7K | 11 | 2015-03-03 |
| WES | Director | 13,120 | $48.77 | $639.8K | -$880.6K | 19 | 2013-12-04 |
| Sarepta Therapeutics, Inc. (AVII) Delisted | Director | 69,411 | — | — | $328.1K | 8 | 2011-09-14 |
Recent Filings · Page 12 of 14
137 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2010-04-22 | Sarepta Therapeutics, Inc. (AVII) Delisted | Grant (A) | — | $0 | EDGAR |
| 2010-04-09 | — | Grant (A) | +1,087 | $0 | |
| 2010-03-10 | WES | Buy (P) | +1,598 | $27.9K | EDGAR |
| 2010-03-03 | — | Buy (P) | +10,000 | $193.8K | |
| 2010-01-12 | — | Grant (A) | +1,173 | $0 | |
| 2010-01-05 | — | Grant (A) | — | $0 | |
| 2009-10-05 | — | Grant (A) | +905 | $0 | |
| 2009-07-09 | — | Grant (A) | +1,000 | $0 | |
| 2009-05-26 | WES | Grant (A) | — | $0 | EDGAR |
| 2009-05-18 | WES | Exer (M) | +7,576 | $111.4K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.